Soleno TherapeuticsSLNO
SLNO
About: Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Employees: 42
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
187% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 15
90% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 29
80% more call options, than puts
Call options by funds: $43M | Put options by funds: $23.8M
25% more funds holding
Funds holding: 114 [Q2] → 142 (+28) [Q3]
24% more capital invested
Capital invested by funds: $1.92B [Q2] → $2.38B (+$459M) [Q3]
7.97% less ownership
Funds ownership: 129.2% [Q2] → 121.23% (-7.97%) [Q3]
10% less funds holding in top 10
Funds holding in top 10: 10 [Q2] → 9 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
55%
upside
Avg. target
$72
60%
upside
High target
$74
64%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 59%upside $72 | Outperform Reiterated | 2 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target | 55%upside $70 | Buy Reiterated | 2 Dec 2024 |
Oppenheimer Leland Gershell 54% 1-year accuracy 31 / 57 met price target | 62%upside $73 | Outperform Maintained | 28 Oct 2024 |
Stifel Dae Gon Ha 38% 1-year accuracy 5 / 13 met price target | 64%upside $74 | Buy Maintained | 1 Oct 2024 |
Financial journalist opinion
Based on 3 articles about SLNO published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million.
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK.
Positive
Seeking Alpha
2 months ago
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects.
Positive
Zacks Investment Research
2 months ago
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
Positive
Zacks Investment Research
2 months ago
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
GuruFocus
2 months ago
SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval
Soleno Therapeutics (SLNO, Financial) experienced a notable stock price increase of 9.11% following positive developments in its regulatory process. This performance far exceeded that of the S&P 500 index, which saw gains of less than 1%.
Positive
The Motley Fool
2 months ago
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval.
Positive
GuruFocus
2 months ago
Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc
On September 30, 2024, Janus Henderson Group PLC, a prominent investment firm, significantly increased its stake in Soleno Therapeutics Inc (SLNO, Financial) by acquiring an additional 804,805 shares. This transaction, executed at a price of $50.49 per share, has raised the firm's total holdings in Soleno to 4,163,678 shares.
Charts implemented using Lightweight Charts™